Kopran Limited · NSE:KOPRAN
Kopran — Q3 FY2025-26 Earnings Presentation
22 slides from Kopran's earnings presentation, Jan 22, 2026
Slide 1: Cover letter to BSE and NSE on investor presentation
January 22, 2026 The Manager The Manager BSE Limited The National Stock Exchange of India Limited Corporate Relationship Department Exchange Plaza, P. J. Towers, Dalal Street, Bandra - Kurla Complex, Bandra (E), Mumbai – 400 001. Mumbai – 400 051. BSE Scrip Code No. 524280 NSE Symbol: KOPRAN Dear Si
Slide 2: Corporate Presentation Q3 - FY 2025-26
CORPORATE PRESENTATION Q3 - FY 2025-26
Slide 3: Disclaimer
This quarterly investor presentation has been prepared by Kopran Limited (‘Kopran’) and does not constitute a prospectus or placement memorandum or an offer to acquire any securities. This presentation or any other documentation or information (or any part thereof) delivered or supplied, should not
Slide 4: Performance
PERFORMANCE • Financial Highlights • Operational Performance • API • Formulation
Slide 5: Financial Highlights
Q-3 Q-2 Q-3 9M PARTICULARS 2025-26 2025-26 2024-25 2025-26 Revenue from Operations 19,428 11,791 16,624 44,741 EBITDA* 2,023 296 2,291 3,733 Finance Costs 267 209 216 730 Forex Gain/Loss -247 -824 -307 -832 Depreciation 442 428 400 1,296 Tax Expenses 140 -170 346 214 Net Profit 934 -992 1,040 687 EB
Slide 6: Operational Performance
OPERATIONAL Sy PERFORMANCE Kopran
Slide 7: APIs Operational Highlights: Segment-wise Revenue Mix
APIs OPERATIONAL HIGHLIGHTS SEGMENT-WISE REVENUE MIX 9M - FY 2025-26 (Rs. in Lakhs) Q3 - FY 2025-26 (Rs. in Lakhs) 61 291 7 129 25 25 17 1,864 525 541 3,070 Anti- Diabetic Anti- Diabetic 982 4,162 Antibiotic-Urological Anti- Infective 142 328 Anti-Hypertensive 1589 103 Antibiotic-Urological Anti-Thr
Slide 8: APIs Operational Highlights: Market-wise Revenue Mix
APIs OPERATIONAL HIGHLIGHTS MARKET-WISE REVENUE MIX 9M - FY 2025-26 (Rs. in Lakhs) Q3 - FY 2025-26 (Rs. in Lakhs) 3257 9313 Export Sales Export Sales Local Sales Local Sales 16562 6748 Total Rs. 25,875 Lakhs Total Rs. 10,005 Lakhs
Slide 9: Formulations Operational Highlights: Region-wise Sales Break-up
Formulations OPERATIONAL HIGHLIGHTS REGION-WISE SALES BREAK-UP 9M - FY 2025-26 (Rs. in Lakhs) Q3 - FY 2025-26 (Rs. in Lakhs) 670 518 1602 646 Africa 3577 Africa CANADA Canada 7742 Latem Latem Middle East and North Middle East and North Africa Africa South Africa South Africa Southeast Asia Southeast
Slide 10: Formulations Operational Highlights: Product-wise Revenue Mix
Formulations OPERATIONAL HIGHLIGHTS PRODUCT-WISE REVENUE MIX 9M - FY 2025-26 (Rs. in Lakhs) Q3 - FY 2025-26 (Rs. in Lakhs) 7543 3740 Non Pen Plant Non Pen Plant Pen Plant Pen Plant 10783 5491 Total Rs. 18,326 Lakhs Total Rs. 9,231 Lakhs
Slide 11: Company Overview
Company Overview • About Us • Business Overview – API • Business Overview – Formulations • Driving Sustainable Growth
Slide 12: A Global Pharmaceutical Company
A GLOBAL PHARMACEUTICAL COMPANY An integrated Pharmaceutical Company, committed to supplying International 50+ Quality Formulations and Active Pharmaceutical Ingredients (APIs) globally. Nations - Export Reach State-of-the-art manufacturing facilities and products with various accreditations and app
Slide 13: API Vertical
API API DEDICATED AND VERSATILE PRODUCT VERTICAL FACILITIES FOR SEGMENT Anti-hypertensive Development, manufacturing and Atenolol Macrolide sale of diverse APIs and Advanced Neuromodulator Intermediates Cephalosporins - Non-Sterile & Sterile Urological One of the leaders in Atenolol
Slide 14: Formulations Vertical
FORMULATIONS PRODUCT SEGMENTS FORMULATIONS VERTICAL Development and manufacturing of oral solid dosages and dry powder formulations for both Penicillin- and Non-Penicillin-based drugs PENICILLIN-BASED NON-PENICILLIN FINISHED ORAL BASED FINISHED Catering 100% export markets of both Regulated and
Slide 15: Strategic Imperatives
STRATEGIC IMPERATIVES GROWTH AND SUSTAINABILITY COST LEADERSHIP Focus on R&D to develop niche, Development of intermediates for APIs high-value/high-volume APIs and intermediates Reducing dependence on China to move towards self sufficiency Capacity expansion Optimising operational cost
Slide 16: Regulatory Compliance
REGULATORY COMPLIANCE OFFERING BEST-IN-CLASS QUALITY THROUGH STRICT COMPLIANCE The Company maintains highest global regulatory standards FORMULATIONS ACCREDITATIONS of manufacturing and quality at its all plants API ACCREDITATIONS Approved by 15 countries including MHRA (UK), SAPHRA South The plant
Slide 17: Financial Performance
FINANCIAL <—, PERFORMANCE Kopran
Slide 18: Snapshot
SNAPSHOT EBITDA * (Rs. in LAKHS) SALES/OTHER INCOME (Rs. in LAKHS) 8,739 8,178 62,920 63,359 7,441 7,290 55,405 50,980 48,813 44,766 5,180 36,013 4,696 3,733 2019-20 2020-21 2021-22 2022-23 2023-24 2024-25 9M-25-26 2019-20 2020-21 2021-22 2022-23 2023-24 2024-25 9M-25-26 FINANCE COSTS (Rs. in LAKHS)
Slide 19: Building Shareholder Value Year on Year
BUILDING SHAREHOLDER VALUE YEAR ON YEAR EBITDA ( Rs. in Lakhs) RoE ( % ) RoCE ( % ) 28.3 8,739 25.3 22.4 8,178 7,441 7,290 20.1 14.5 5,180 4,696 3,733 11.8 11.5 9.4 8.4 11 6.3 7.6 1.4 1.3 2019-20 2020-21 2021-22 2022-23 2023-24 2024-25 9M-25-26 2019-20 2020-21 2021-22 2022-23 2023-24 2024-25 9M-25-2
Slide 20: Multi-year financial summary (Rs. in Lakhs)
(Rs. in Lakhs) PARTICULARS Q3 FY FY FY FY FY FY FY 2025-26 2024-25 2023-24 2022-23 2021-22 2020-21 2019-20 Equity Share Capital 4,829 4,829 4,821 4,821 4,821 4,325 4,325 Other Equity 46,202 47,006 44,303 39,104 37,796 20,178 14,643 Net Worth 51,030 51,835 49,125 43,925 42,617 24,503 18,968 Fixed Ass
Slide 21: Board of Directors
BOARD OF DIRECTORS MR. SURENDRA SOMANI MR. ADARSH RAJENDRA SOMANI MR. VARUN SURENDRA SOMANI CHAIRMAN & MANAGING DIRECTOR DIRECTOR DIRECTOR MR. CHANDRESH GANDHI MRS. MAMTA BIYANI MR. NARAYAN ATAL INDEPENDENT DIRECTOR INDEPENDENT DIRECTOR INDEPENDENT DIRECTOR
Slide 22: About Kopran Limited
ABOUT KOPRAN LIMITED: Kopran Limited is an integrated Pharmaceutical Company, committed to manufacturing and supplying International Quality Formulations and APIs worldwide. Kopran's manufacturing facilities and products have accreditations across all the continents. Research & Development for New P